Zepbound is the brand name Eli Lilly uses for tirzepatide when prescribed for chronic weight management or obstructive sleep apnea (OSA); the same molecule is sold as Mounjaro for type 2 diabetes. The FDA approved Zepbound for obesity in November 2023 under NDA 217806 and added the OSA indication in December 2024. That second approval matters enormously for Medicare beneficiaries, because it created the only path into standard Part D coverage: Medicare Part D has excluded drugs used specifically for weight loss since the Medicare Modernization Act of 2003, but OSA is treated as a separate, medically accepted indication outside that exclusion. Roughly 42 million Medicare beneficiaries carried Part D or Medicare Advantage drug coverage in 2026, and a growing share live with obesity, OSA, or both, which makes the distinction between these two indications the single most important fact for anyone asking whether Medicare pays for Zepbound.
Medicare's coverage landscape for Zepbound shifted again in 2026. Beginning July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge, a demonstration program that lets eligible Part D beneficiaries access the Zepbound KwikPen (not the single-dose vial) for a qualifying weight-related diagnosis at a flat $50 monthly copay, without needing the OSA diagnosis code. The Bridge runs through December 31, 2027 while CMS studies a longer-term coverage model. Enrollment happens automatically once a prescriber submits prior authorization; there is no separate application form, and every Part D sponsor nationwide participates without the option to opt out. Patients who do not meet Bridge criteria, or who need the single-dose vial formulation, still fall back to the OSA-only standard Part D pathway or to the full retail list price. Compare that path against Wegovy's Medicare coverage, the competing GLP-1 that reached a Part D cardiovascular pathway earlier.
The Inflation Reduction Act of 2022 changed how Medicare pays for many high-cost drugs, but tirzepatide is not one of them yet. CMS selected the first 10 drugs for Medicare price negotiation in 2023, with Maximum Fair Prices effective January 1, 2026, and a second round of 15 drugs in January 2025, including Novo Nordisk's semaglutide products Ozempic, Wegovy, and Rybelsus, with Maximum Fair Prices effective January 1, 2027. Zepbound and Mounjaro were left off both lists, and a January 2026 announcement of the third negotiation cycle (effective 2028) also did not include tirzepatide. Medicare beneficiaries paying for Zepbound in 2026 are protected by the general $2,100 Part D annual out-of-pocket cap rather than a negotiated price, which is a meaningfully different cost structure than what applies to Ozempic and Wegovy starting in 2027.
What Zepbound Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same zepbound can cost many times more at a hospital than at your local pharmacy:
2026 Zepbound Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare Part D (OSA indication) | Plan formulary copay, capped at $2,100/year (2026) | Requires ICD-10 diagnosis code G47.33 plus prior authorization; standard Part D rules apply |
| Medicare GLP-1 Bridge (obesity, Jul 2026 - Dec 2027) | $50/month flat copay | CMS demonstration program; KwikPen only, not vials; copay excluded from deductible and $2,100 cap |
| Medicare Advantage prescription drug plan (MAPD) | Same Part D rules; formulary and PA vary by plan | Some MA-PD plans dropped Zepbound in 2025; CVS Caremark reinstated it as co-preferred October 1, 2026 |
| Medicaid (dual-eligible beneficiaries) | $1 - $8/prescription, where covered | About 13 states covered GLP-1s for obesity under fee-for-service as of early 2026; varies by state |
| Retail pharmacy (no Medicare coverage) | $1,086/month (list price) | Full WAC if your plan denies coverage; LillyDirect self-pay is not available to Medicare beneficiaries |
Medicare GLP-1 Bridge copay figures reflect the CMS demonstration effective July 1, 2026 through December 31, 2027. Part D formulary copays vary by plan and region; confirm your specific plan's tier placement at Medicare.gov.
Source: CMS Medicare GLP-1 Bridge, CMS Medicare Part D 2026 benefit parameters, KFF Medicaid GLP-1 tracker
Why Hospitals Charge So Much
Zepbound rarely appears on a hospital bill because it is a self-administered, once-weekly outpatient injection rather than a drug infused or administered by clinical staff. Medicare Part B, which covers hospital outpatient and physician-administered drugs, does not pay for Zepbound at all. There is no HCPCS J-code for tirzepatide because it is dispensed through the pharmacy benefit (Part D), not the medical benefit (Part B), which is why the Part B deductible and coinsurance rules that apply to infused drugs do not apply here.
Hospitals that do bill for Zepbound, typically because a patient continued their home dose during an inpatient admission, apply the same facility markup logic used for any home medication brought into the hospital. Itemized charges can run several times the $1,086 monthly list price for a single dose. Medicare Part A generally covers medications administered during a covered inpatient stay as part of the bundled DRG payment, so a separate Zepbound line item on a Medicare inpatient bill is worth disputing directly with the hospital billing office rather than paying as billed.
Prior authorization denials, not hospital markups, are the more common cost problem for Zepbound and Medicare. Because standard Part D covers only the OSA indication and the GLP-1 Bridge has its own eligibility rules, most Zepbound billing disputes for Medicare beneficiaries trace back to a missing diagnosis code or an incomplete prior authorization rather than a facility overcharge, which is why the common billing errors and appeal steps below matter more for this drug than a typical hospital markup dispute.
Patient Assistance Programs
Eli Lilly does not offer a traditional income-based patient assistance program for Zepbound, and its two commercial affordability programs, LillyDirect self-pay and the Zepbound Savings Card, are both closed to Medicare beneficiaries by law. For Medicare enrollees, the realistic paths to a lower Zepbound cost are the standard Part D OSA benefit, the new Medicare GLP-1 Bridge, and, for dual-eligible beneficiaries, state Medicaid coverage.
Patient assistance programs for Zepbound| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Medicare GLP-1 Bridge (CMS demonstration) | $50/month flat copay for the Zepbound KwikPen when prescribed for a qualifying weight-related diagnosis; no income test; runs July 1, 2026 through December 31, 2027 | cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge |
| Standard Medicare Part D OSA Coverage | Plan formulary copay counting toward the $2,100 annual out-of-pocket cap; requires OSA diagnosis (ICD-10 G47.33) and prior authorization | medicare.gov/plan-compare |
| LillyDirect Self Pay Journey Program | $299 - $449/month depending on dose, but by program terms it cannot be used by anyone enrolled in Medicare or Medicaid | lilly.com/lillydirect/medicines/zepbound |
| State Medicaid GLP-1 coverage (dual-eligible beneficiaries) | $1 - $8/prescription copay in states that cover GLP-1s for obesity; roughly 13 states covered as of early 2026 | medicaid.gov |
Manufacturer copay cards and cash-pay programs like the Zepbound Savings Card and LillyDirect are barred from use by Medicare, Medicaid, TRICARE, and VA beneficiaries under the federal anti-kickback statute (42 U.S.C. § 1320a-7b). If you have Medicare, apply through the Medicare GLP-1 Bridge or your Part D plan's OSA benefit instead of chasing a manufacturer coupon that legally cannot apply to your claim.
Source: CMS Medicare GLP-1 Bridge, LillyDirect Zepbound Self-Pay Terms, KFF Medicaid GLP-1 tracker
Medicare Part D
Medicare Part D covers Zepbound when the prescription documents moderate-to-severe obstructive sleep apnea (OSA) in a patient with obesity, using ICD-10 diagnosis code G47.33. This OSA pathway exists only because the FDA expanded Zepbound's label in December 2024; before that approval, tirzepatide products had no route into standard Part D formularies for anyone without diabetes. Most Part D plans place Zepbound on a high formulary tier and require prior authorization, so your prescriber's office needs to document the sleep study and comorbid obesity diagnosis before the plan will approve the claim.
The Medicare GLP-1 Bridge changed the picture for beneficiaries who need Zepbound for obesity alone rather than OSA. From July 1, 2026 through December 31, 2027, CMS covers the Zepbound KwikPen for beneficiaries with a body mass index (BMI) of 30 or higher and a weight-related condition, a BMI of 27 or higher with certain comorbidities, or a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), at a flat $50 monthly copay. That $50 copay does not count toward your Part D deductible or the annual out-of-pocket cap, so it sits outside the normal benefit structure. Every Part D sponsor participates automatically; there is no plan-level opt-out available.
Once a Zepbound claim is covered under standard Part D for OSA, your spending applies to the 2026 annual out-of-pocket cap of $2,100. Once you reach that cap across all covered Part D drugs combined, you pay $0 for the rest of the calendar year. Dual-eligible beneficiaries (Medicare plus Medicaid) may pay far less through Extra Help, the Part D Low-Income Subsidy, and beneficiaries in states that cover GLP-1s under Medicaid may have an additional coverage path if their Medicare Part D plan denies the claim.
Common Zepbound Billing Errors
Zepbound claims for Medicare beneficiaries get denied or overbilled for predictable reasons. Check for these before assuming you owe the full list price:
- Missing OSA diagnosis code: Standard Part D coverage requires ICD-10 code G47.33 (obstructive sleep apnea) on the claim. A prescription written only for 'obesity' or 'weight management' without this code will be denied under standard Part D rules.
- Prescription written for the single-dose vial instead of the KwikPen: The Medicare GLP-1 Bridge covers only the Zepbound KwikPen formulation. A vial prescription will not process under the Bridge's $50 copay even if the patient otherwise qualifies.
- Bridge copay charged twice or miscounted toward the deductible: The $50 Medicare GLP-1 Bridge copay is separate from standard Part D cost-sharing and should not accumulate toward your deductible or the $2,100 out-of-pocket cap. If a pharmacy claim shows it counting toward the cap, ask the pharmacist to rerun it under the Bridge benefit code.
- Manufacturer savings card rejected, then billed at full price without checking Bridge eligibility: Some pharmacies attempt to run the Zepbound Savings Card for a Medicare patient, which fails under federal law, and then default to full cash price instead of first checking GLP-1 Bridge or standard Part D eligibility.
- Medicare Advantage plan formulary lapse: Several Medicare Advantage prescription drug plans, including some administered by CVS Caremark, dropped Zepbound from their formulary in 2025 before partially reinstating it in October 2026. Confirm your specific plan's current formulary tier at Medicare.gov before assuming a denial means permanent exclusion.
- Prior authorization expired or not renewed annually: Part D prior authorizations for Zepbound typically require annual renewal with updated clinical documentation. A claim denied mid-year is often a lapsed PA rather than a brand-new denial.
Frequently Asked Questions
Does Medicare cover Zepbound in 2026?
Yes, but only under specific conditions. Standard Medicare Part D covers Zepbound when prescribed for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, using diagnosis code G47.33, subject to prior authorization and your plan's formulary tier. Starting July 1, 2026, the Medicare GLP-1 Bridge also covers the Zepbound KwikPen for obesity-only diagnoses at a flat $50 monthly copay through December 31, 2027. Medicare does not cover Zepbound for weight loss outside of these two specific pathways.
Is there a generic or biosimilar for Zepbound?
No. As of 2026, no FDA-approved generic tirzepatide exists, and none is expected before Eli Lilly's composition-of-matter patents expire around 2036. Tirzepatide is a small-molecule drug, not a biologic, so it will eventually face generic competition through an Abbreviated New Drug Application (ANDA) rather than biosimilar competition. Compounded tirzepatide from outsourcing facilities was available during 2022-2024 shortages, but FDA restrictions tightened in 2025 as brand-name supply normalized.
How do I apply for the Medicare GLP-1 Bridge for Zepbound?
Ask your prescriber to submit a prior authorization to your Part D plan documenting one of three qualifying criteria: a BMI of 30 or higher with a weight-related condition, a BMI of 27 or higher with certain comorbidities, or a MASH diagnosis. Your prescription must be written for the Zepbound KwikPen, not the single-dose vial. There is no separate application form or income test; once your Part D plan approves the prior authorization, the $50 monthly copay applies automatically at any participating pharmacy nationwide through December 31, 2027.
Can I use the Zepbound Savings Card or LillyDirect if I have Medicare?
No. Federal anti-kickback law (42 U.S.C. section 1320a-7b) bars manufacturer copay cards, including the Zepbound Savings Card, from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. LillyDirect's self-pay program explicitly excludes Medicare and Medicaid beneficiaries by its own terms of service. If you have Medicare, your options are the standard Part D OSA benefit, the Medicare GLP-1 Bridge, or, if you're dual-eligible, your state Medicaid GLP-1 policy.
What if my Medicare Advantage or Part D plan denies coverage for Zepbound?
Request a written denial notice, then file a Part D redetermination request within 60 days with your prescriber's supporting documentation of the OSA diagnosis or GLP-1 Bridge eligibility criteria. Ask your prescriber to request an expedited review if delay would harm your health, or to file a step-therapy exception if the plan requires you to try a different GLP-1 first. If the redetermination is denied, you can escalate to an Independent Review Entity and, if the dollar amount qualifies, an Administrative Law Judge hearing.
Does the IRA negotiated Maximum Fair Price apply to Zepbound in 2026?
No. Tirzepatide, sold as Zepbound and Mounjaro, was not selected in the first round of Medicare drug price negotiation (Maximum Fair Prices effective January 1, 2026) or the second round announced in January 2025 (effective January 1, 2027), which instead included Novo Nordisk's semaglutide products Ozempic, Wegovy, and Rybelsus. Zepbound costs under Medicare in 2026 are governed by the standard $2,100 Part D out-of-pocket cap and the Medicare GLP-1 Bridge copay, not a negotiated price.
What does Zepbound cost without Medicare coverage in 2026?
The wholesale list price for the Zepbound KwikPen is $1,086 per month regardless of dose. Medicare beneficiaries who don't qualify for the OSA pathway or the GLP-1 Bridge, and whose plan denies coverage, generally face this full list price, because LillyDirect's discounted self-pay tier ($299 to $449 per month) is not available to anyone on Medicare or Medicaid. Confirm your plan's formulary status at Medicare.gov before assuming you'll pay full price.
How does Zepbound's Medicare coverage compare to Wegovy's?
Both drugs reached Medicare coverage through similar routes, but with different timing. Wegovy gained a standard Part D pathway in 2024 when CMS clarified that GLP-1s prescribed to reduce cardiovascular risk in patients with heart disease and obesity are covered, and semaglutide was later selected for IRA negotiation with a Maximum Fair Price effective January 1, 2027. Zepbound's standard pathway is narrower, limited to the OSA indication, and tirzepatide has not been selected for IRA negotiation. Both drugs are covered under the same July 2026 Medicare GLP-1 Bridge program for obesity-only diagnoses.
